Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...

Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 ...

Along with the layoffs, the reshuffle includes prioritisation of pipeline assets with the “highest probability of success.” ...

Mixed options sentiment in Moderna (MRNA), with shares down $1.15 near $25.56. Options volume running well above average with 49k contracts traded ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

The greater part of third quarter earnings results are in the rearview mirror, though investors this week are looking to ...

After a generation of stagnation, interest in U.S. nuclear energy is sky high, thanks to artificial intelligence’s voracious ...

Delaware says COVID-19 vaccines are available at state clinics, regardless of insurance status. But only 2 clinics carried ...